Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MDU Resources Group Inc. Common Stock (Holding Company) (MDU) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance

MDU Resources Group Inc. Common Stock (Holding Company)Trade
uniQure N.V. Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

MDU Resources Group Inc. Common Stock (Holding Company) vs uniQure N.V. Ordinary Shares — how do they compare? MDU Resources Group Inc. Common Stock (Holding Company) trades at $18.56 (market cap $3.92B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: MDU Resources Group Inc. Common Stock (Holding Company) is far larger — about 2.6× uniQure N.V. Ordinary Shares's market cap, and MDU Resources Group Inc. Common Stock (Holding Company) pays a 3.03% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold MDU Resources Group Inc. Common Stock (Holding Company) for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.

MDUQURE
Market Cap
$3.92B$1.48B
Volume
1,027,6562,488,780
Sector
UtilitiesHealth
52-Week High
$22.80$70.59
52-Week Low
$18.39$9.03
Typical Hold Time
0 Days0 Days
Enterprise Value
$6.45B$728.62M
Dividend Yield
3.03%—

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MDU
100% Buy0% Sell
Avg holding period · 0 Days
QURE
100% Buy0% Sell
Avg holding period · 0 Days

About MDU Resources Group Inc. Common Stock (Holding Company)

MDU Resources Group, Inc. is a US holding company operating regulated electric and natural gas utility services alongside a construction materials and services business supplying asphalt, concrete, and aggregates.

Read more on MDU →

About uniQure N.V. Ordinary Shares

uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.

Read more on QURE →